Synlogic, Inc. (NASDAQ:SYBX) Short Interest Update

Synlogic, Inc. (NASDAQ:SYBX) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 11,100 shares, an increase of 22.0% from the June 30th total of 9,100 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 21,400 shares, the days-to-cover ratio is currently 0.5 days.

Synlogic Stock Up 1.2 %

Shares of NASDAQ SYBX traded up $0.02 during mid-day trading on Monday, reaching $1.69. 1,385 shares of the company were exchanged, compared to its average volume of 72,380. Synlogic has a 52 week low of $1.35 and a 52 week high of $8.85. The company’s 50 day moving average price is $1.57 and its 200 day moving average price is $1.96. The stock has a market capitalization of $19.79 million, a PE ratio of -0.17 and a beta of 0.92.

Synlogic (NASDAQ:SYBX) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($1.80). The firm had revenue of $0.01 million for the quarter. Synlogic had a negative return on equity of 189.99% and a negative net margin of 2,284.65%. On average, sell-side analysts predict that Synlogic will post -2.48 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Synlogic stock. Armistice Capital LLC raised its position in shares of Synlogic, Inc. (NASDAQ:SYBX) by 75.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,055,000 shares of the biotechnology company’s stock after buying an additional 455,126 shares during the period. Armistice Capital LLC owned about 11.48% of Synlogic worth $4,062,000 at the end of the most recent reporting period. Institutional investors own 63.40% of the company’s stock.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.